AT-07 A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: PATIENT REPORTED OUTCOMES (PRO) FROM A CERN CLINICAL TRIAL

Lignende værker

• AT-23 A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL
  af: Gilbert, Mark, et al.
  Udgivet: (2014)
• RARE-24. OBJECTIVE RESPONSE AND CLINICAL BENEFIT IN RECURRENT EPENDYMOMA IN ADULTS: FINAL REPORT OF CERN 08-02: A PHASE II STUDY OF DOSE-DENSE TEMOZOLOMIDE AND LAPATINIB
  af: Armstrong, Terri, et al.
  Udgivet: (2018)
• A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma
  af: Gilbert, Mark R, et al.
  Udgivet: (2020)
• Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients
  af: Vera-Bolanos, Elizabeth, et al.
  Udgivet: (2015)
• An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)
  af: DeWire, Mariko, et al.
  Udgivet: (2015)